For research use only. Not for therapeutic Use.
EPI-589, a quinone derivative, is a safe and well tolerated oxidoreductase enzyme inhibitor. EPI-589 has the potential for the treatment of amyotrophic lateral sclerosis (ALS)[1].
EPI-589 exhibits a significant improvement in cerebrospinal fluid (CSF) and plasma-based biomarkers known to be associated with neuroinflammation and ALS disease progression[2].
| Catalog Number | I017136 |
| CAS Number | 1147883-03-1 |
| Synonyms | (2R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide |
| Molecular Formula | C14H19NO4 |
| Purity | ≥95% |
| InChI | InChI=1S/C14H19NO4/c1-7-8(2)12(17)10(9(3)11(7)16)5-6-14(4,19)13(15)18/h19H,5-6H2,1-4H3,(H2,15,18)/t14-/m1/s1 |
| InChIKey | BAANPNDZFYBQIB-CQSZACIVSA-N |
| SMILES | CC1=C(C(=O)C(=C(C1=O)C)CCC(C)(C(=O)N)O)C |
| Reference | [1]. BioElectron’s EPI-589 Shows Positive Results in ALS Patients in Phase 2a Trial [2]. Phase IIa trial of EPI-589 in ALS shows improvement in CSF |
